December 22, 2016 / 12:25 PM / 7 months ago

BRIEF-Ironwood and Allergan report topline Phase IIB data

1 Min Read

Dec 22 (Reuters) - Ironwood Pharmaceuticals Inc

* Ironwood Pharmaceuticals - To engage with U.S. FDA to discuss Phase III development plans; trials in adults with IBS-C expected to begin in H2 of 2017

* Ironwood Pharmaceuticals - Co, Allergan pursuing patent protection for CR1 and CR2 that, if issued, is expected to provide patent coverage into mid-2030s

* Press Release - Ironwood and Allergan report topline phase IIB data supporting advancement of linaclotide colonic release-1 (CR1) in IBS-C Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below